文章：

多发性骨髓瘤的髓外病变

Extramedullary disease in multiple myeloma

原文发布日期：2021-09-29

DOI: 10.1038/s41408-021-00527-y

类型: Review Article

开放获取: 是

英文摘要：

When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The pathogenetic mechanisms are not completely understood and it is generally associated with high-risk cytogenetics which portends poor outcomes. There is a rising incidence of EMD in the era of novel agents, likely a reflection of longer OS, with no standard treatment approach. Patients benefit from aggressive chemotherapy-based approaches, but the OS and prognosis remains poor. RT has been used for palliative care. There is a need for large prospective trials for development of treatment approaches for treatment of EMD.
 

摘要翻译： 

当克隆浆细胞在远离骨髓的解剖部位生长，或从突破骨皮质的骨病变处连续生长时，称为髓外多发性骨髓瘤（EMD）。从治疗和生物学角度来看，EMD仍然具有挑战性。其发病机制尚未完全明确，通常与高风险细胞遗传学相关，预示着不良预后。在新药时代，EMD的发病率有所上升，这可能反映了患者总生存期延长，但目前尚无标准治疗方案。患者可从积极的化疗方案中获益，但总生存期和预后仍然较差。放疗已用于姑息治疗。未来需要开展大型前瞻性试验以制定EMD的治疗方案。

原文链接：

Extramedullary disease in multiple myeloma